Novo Nordisk's parent to buy Catalent for $16.5 billion
Novo Nordisk has notched a win in its race to boost output of its popular obesity drug Wegovy, with its parent company announcing it was buying Catalent, a key manufacturing subcontractor of the product, for $16.5 billion.
Business
• 06 Feb 24
